Video

5-Year Follow-Up Data For CPX-351 in AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP

Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.

Related Videos
Image Credit: © nimito - stock.adobe.com
Image Credit: © Beaunitta Van Wyk/peopleimages.com - stock.adobe.com
Image Credit: © sofiko14 - stock.adobe.com
Image Credit: © hamad - stock.adobe.com
Image Credit: © Anastasiia - stock.adobe.com
hematological cancer/Image Credit: © nikola-master - stock.adobe.com
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
MP Studio - stock.adobe.com
Related Content
Image Credit: © Jasmine - stock.adobe.com
October 21st 2024

Momelotinib Demonstrates Efficacy, Safety Compared With Ruxolitinib for Treatment of Myelofibrosis

Alexandra Gerlach, Associate Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

t cells or cancer cells
October 17th 2024

Nivolumab-Chemotherapy Combination Lengthens Survival, Causes Manageable Adverse Effects in Stage III or IV Classic Hodgkin Lymphoma

Luke Halpern, Assistant Editor
Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia
September 26th 2022

Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia

FDA Approves Marstacimab-hncq for Adults, Adolescents With Hemophilia A or B Without Inhibitors
October 11th 2024

FDA Approves Marstacimab-hncq for Adults, Adolescents With Hemophilia A or B Without Inhibitors

Aislinn Antrim, Assistant Managing Editor
Image Credit: © Anastasiia - stock.adobe.com
October 9th 2024

Ciltacabtagene Autoleucel Demonstrates Promising Efficacy, Safety in Real-World Study

Alexandra Gerlach, Associate Editor